- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 915636, 7 pages
Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control
1Center for Quantitative Sciences, Vanderbilt University, Nashville, TN 37027, USA
2Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37037, USA
3Department of Biochemistry, Vanderbilt University, Nashville, TN 37027, USA
Received 3 September 2013; Accepted 24 September 2013
Academic Editor: Zhongming Zhao
Copyright © 2013 Yan Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Exome sequencing using next-generation sequencing technologies is a cost-efficient approach to selectively sequencing coding regions of the human genome for detection of disease variants. One of the lesser known yet important applications of exome sequencing data is to identify copy number variation (CNV). There have been many exome CNV tools developed over the last few years, but the performance and accuracy of these programs have not been thoroughly evaluated. In this study, we systematically compared four popular exome CNV tools (CoNIFER, cn.MOPS, exomeCopy, and ExomeDepth) and evaluated their effectiveness against array comparative genome hybridization (array CGH) platforms. We found that exome CNV tools are capable of identifying CNVs, but they can have problems such as high false positives, low sensitivity, and duplication bias when compared to array CGH platforms. While exome CNV tools do serve their purpose for data mining, careful evaluation and additional validation is highly recommended. Based on all these results, we recommend CoNIFER and cn.MOPs for nonpaired exome CNV detection over the other two tools due to a low false-positive rate, although none of the four exome CNV tools performed at an outstanding level when compared to array CGH.
Next-generation sequencing technology, piloted by the Illumina platform, has substantially decreased the cost of sequencing on large genomic regions. However it is still financially prohibitive to perform whole genome sequencing on a large number of subjects, especially for large scale genetic epidemiology association studies, at a sufficient depth for accurate genotype calls. The human exome represents about 1–3% of the human genome with approximately 30–50 million base pairs but accounts for over 85% of all mutations identified in Mendelian disorders . As a result, exome sequencing is currently an attractive and practical approach for investigating coding variations.
Exome sequencing is typically used to identify single nucleotide polymorphisms (SNPs), somatic mutations (through paired sample comparison), and small and large structural variations. A lesser-known application of exome sequencing data is to identify copy number variations (CNV). CNVs are a structural variation in which cells have an abnormal number of copies of one or more sections of the DNA. Normal cells are diploid containing two copies of DNA and abnormal CNVs refer to large regions of the chromosome that have been deleted or duplicated. CNV characterization is important for both the basic understanding of many diseases and their diagnoses. CNVs have been linked to various diseases including autism , obesity , breast cancer , colorectal cancer , and lung cancer .
Traditionally, CNV detection has been performed with cytogenetic techniques such as fluorescent in situ hybridization, array comparative genomic hybridization (array CGH), and with virtual karyotyping using SNP arrays. Array CGH is commonly considered to be a reliable method for discovering novel CNVs because of the relatively even distribution of probes . Many high-impact copy number studies [8–10] were based on results derived from array CGH methods.
Whole genome sequencing data are relatively even in coverage, thus making it ideal for CNV discovery. Many CNV methods [11–17] have been developed for whole genome sequencing data. On the other hand, exome sequencing’s depth is strongly affected by the enrichment regions, thus making it less ideal for CNV discovery. However, given the popularity of exome sequencing and the massive amount of exome sequencing data accumulated thus far, there is much interest in inferring CNVs from exome sequencing data. Thus, multiple CNV tools targeting exome sequencing data have been developed. We have cataloged sequencing data based CNV tools in Table S1 in the Supplementary Material available online at http://dx.doi.org/10.1155/2013/915636.
To determine if exome sequencing could provide reliable CNV detection, we performed array CGH and exome sequencing on 16 breast cancer cell lines. The data obtained from this study provides us an opportunity to evaluate the CNV discovery method based on exome sequencing while using array CGH as the reference. To date, there have been seven CNV tools targeting exome sequencing data: ExomeCNV , CoNIFER , cn.MOPS , exomeCopy , ExomeDepth , CNANorm , and CONTRA . CNANorm, CONTRA, and ExomeCNV are specifically designed for paired tumor and normal samples. The other four do not require paired sample as input. These four tools cover a unique aspect of exome sequencing data. As exome sequencing become more commercially affordable, large epidemiology studies which only have blood samples available are more likely to choose exome sequencing over SNP array. The unpaired exome CNV tools will become the only suitable tools for CNV analysis. In this study, we systematically evaluated the performance of these four tools against each other using array CGH as the reference. We present our findings in detail and make a recommendation for the best unpaired exome CNV discovery tool based on our findings.
2. Materials and Methods
We performed array CGH on 16 breast cancer cell lines (Table S2) using the Agilent SurePrint G3 Human CGH Microarray Kit. This array CGH kit contains 963,029 distinct probes with 2.1 KB overall median probe spacing. The array CGH chips were scanned using the GenePix 4000B scanner, and probe intensities were normalized using Agilent’s Feature Extraction software. CNVs were called using the Aberration Detection Method 2 (ADM2), a very broadly used CNV detection method for array CGH platform through GeneSpring Software. Exome sequencing data analysis was also performed on the same 16 breast cancer cell lines using Illumina’s TrueSeq exome enrichment kit on Illumina’s HiSeq 2000 platform. The sequencing reads are pair end 75 base pair long. The pooled, barcoded raw data produced by the Illumina HiSeq 2000 high-throughput sequencer was first split using barcode splitting software to obtain raw data for each individual. The raw data were aligned using BWA , which was designed based on the Borrows-Wheeler Transformation. The Human reference genome HG19 was used for alignment. The aligned BAM  files were locally realigned using the Genome Analysis Toolkit (GATK)  developed by the Broad Institute. The local realignment step aims to correct misalignment caused by the presence of insertions or deletions (indels). To further increase the local realignment accuracy, after local realignment, we performed base quality score recalibration on the realigned BAM files using GATK’s recalibration tool. The recalibration tool attempts to correct for variations in quality with machine cycle and sequence context. The resulting BAM files contain not only more accurate base quality scores but also more widely dispersed ones. The recalibrated BAM files were filtered by removing all reads with mapping quality Phred score  less than 20 and all bases with base quality Phred score less than 20 (meaning that the probability of the base call being wrong is less than 0.01). CNVs on the processed BAM files were called using CoNIFER, cn.MOPS, exomeCopy, and ExomeDepth. Each of the four tools provides a wide range of parameters. We either consulted with the authors of the tools for the best parameters or used the author recommended parameters for the analysis. The exact command line used for each tool is listed in Table S3. Results of CNV detection from these four tools were compared to the array CGH results to determine the strength and weakness of each program.
3. Results and Discussion
We generated high quality exome sequencing data using the Illumina TrueSeq enrichment kit on the HiSeq 2000 platform. All samples’ raw data passed the initial quality control using FASTQC. On average, each sample had 117 million (range: 73 to 183 million) reads sequenced. The average capture efficiency was 48% (range: 39% to 62%). No notable quality issues were observed for the exome sequencing data (Table S2).
Across all 16 samples, array CGH identified 5,225 CNVs. Among the four exome CNV tools, exomeCopy identified the most CNVs (3,398), and CoNIFER identified the least (267). ExomeDepth (1,581) and cn.MOPS (1,214) identified a moderate number of CNVs (Figure 1(a)). The median CNV length identified by array CGH was 261,400 base pairs (range: 959 to 146,900,000 base pairs). ExomeDepth and exomeCopy identified the CNVs with longer average length than did array CGH, while CNVs identified by CoNIFER and cn.MOPS had shorter average length compared to array CGH (Figure 1(b)).
We also determined the deletion-duplication ratio for array CGH and the four exome CNV tools by sample. Each sample has distinct molecular characteristics that result in distinct deletion and duplication ratios. Consistently observing more duplication than deletions or vice versa across all samples may be an indication of an algorithm-specific bias. For array CGH, across all 16 samples, we observed 9 samples with more duplication and 7 samples with more deletions, a rather ideal scenario (Figure 2(a)). For exomeCopy and cn.MOPS, we observed 10 samples with more duplication and 6 samples with more deletions (Figures 2(b) and 2(c)). For ExomeDepth, we observed 11 samples with more duplication and 5 samples with more deletions (Figure 2(d)). For CoNIFER, we observed 14 samples with more duplication and 2 samples with more deletions (Figure 2(e)). We conducted paired Wilcoxon signed rank tests to see if there is any duplication or deletion bias. We found that array CGH showed unbiased duplication and deletions with value = 0.11, exomeCopy also showed unbiased duplication and deletions with value = 0.1. CoNIFER had strong bias toward duplication with values equal to 0.025. ExomeDepth and Cn.MOPS showed marginal bias toward duplication with value = 0.064. To identify the exome CNV tool with the most similar deletion duplication ratio, we conducted pairwise Kullback-Leibler divergence distance on both duplication and deletions proportions (Table 1). The values in Table 1 are measures of the difference between the tested method and the array CGH method, with smaller values indicating less difference. For both duplication and deletions, cn.MOPS showed the shortest distance to array CGH, with 0.15 for deletions and 0.36 for duplication.
To measure the consistency with array CGH, we determined the overlap of CNVs identified between each of the exome CNV tools with array CGH. Overlapping CNVs were defined as regions that share at least 50% of their base pairs. We also used a less strict option where two CNVs are considered consistent if only 1% of the base pairs overlapped. However, regardless of which option we use, the results were very similar, since if two CNVs from two methods overlapped, most of them overlapped by at least 50% (Table S4). Compared to the array CGH platform, cn.MOPS had the best true positive rate for duplication with 76.9%, and CoNIFER had the best true positive rate for deletions with 83.8% (Figure 3). ExomeDepth and exomeCopy had comparable true positive rates for duplication with CoNIFER but lower true positive rates for deletions. Also interestingly, all four exome CNV tools identified some CNVs with opposite direction (deletion instead of duplication or vice versa) compared to array CGH. ExomeDepth and exomeCopy had relatively low proportion of CNVs with opposite direction on duplication (2.5% and 3.0%) but a moderate proportion of CNVs with opposite direction on deletion (8.9% and 10.9%), while cn.MOPS and ConNIFER had a relatively low proportion of CNVs with opposite direction (3.5% and 2.5% for duplication, 6.3% and 5.9% for deletion). CoNIFER and cn.MOPS detected CNVs with a much lower false-positive rate. In such a scenario, CoNIFER and cn.MOPS are much more desirable, because it is impossible to tell true-positives from false-positives without any prior knowledge. ExomeDepth and exomeCopy also demonstrated comparable performance for detecting duplication with CoNIFER.
Exome sequencing is widely used to conduct genomic research. Identifying CNVs through exome sequencing data has been a popular topic over the last few years. Compared to array-based methods, identifying CNVs through exome sequencing data has some shortcomings. First, the exons within the genome are not evenly placed. They are located at fixed positions, unlike probes which can be designed to be placed evenly across the whole genome. Thus if only depth information from unevenly located exons can be used for CNV assessment then CNV detection over a long intergenic region would be unreliable. Also, a probe can be designed to avoid hybridization at problematic genomic regions such as regions with high GC content. A high GC content region can affect the sequencing depth for exome sequencing, which makes identifying CNVs using exome sequencing data even more complicated. Additional normalization to correct noise caused by effects such as GC content is desirable.
With these known difficulties, many exome CNV tools have been developed over the last few years. In this study, we evaluated the effectiveness of four popular unpaired exome CNV tools: cn.MOPS, CoNIFER, ExomeDepth, and exomeCopy using 16 breast cancer cell lines. We identified CNVs using these four tools and verified the results against array CGH results from the same samples. CoNIFER and cn.MOPS identified much fewer CNVs but with a high true-positive rate. ExomeDepth and exomeCopy produced comparable performance for duplication detection with CoNIFER. In terms of duplication-deletion proportion, we found that with the exception of exomeCopy, the exome CNV tools showed a significant bias toward duplication. This could be the result of an artifact of the exome CNV algorithm that underestimates the normal copy number based on depth. Using the Kullback-Leibler divergence distance, we found that cn.MOPS is the closest to array CGH in terms of duplication or deletion proportion across samples. Based on all these results, we recommend CoNIFER and cn.MOPS for nonpaired exome CNV detection over the other two tools due to a low false-positive rate, although none of the four exome CNV tools performed at an outstanding level when compared to array CGH. In summary, there is value in identifying CNVs using exome sequencing data but extra caution needs to be taken into consideration due to the high false positive rate. Identifying CNVs is almost never the primary goal of the exome sequencing study, and it should stay that way due to the noise introduced by exome sequencing data. Identifying CNVs using exome sequencing data is potentially a good secondary data mining technique. Based on our comparison of the methods, results generated from exome CNV tools should be evaluated thoroughly, and additional validation is highly recommended to eliminate false-positives and to ensure quality data.
Using array CGH result as control, we systematically compared four popular exome CNV tools (CoNIFER, cn.MOPS, exomeCopy, and ExomeDepth) on exome sequencing data generated from 16 breast cancer cell lines. Among evaluated four tools, we recommend CoNIFER and cn.MOPS for nonpaired exome CNV detection due to a low false-positive rate. Our results suggest that exome CNV tools are subjected to high false positive rat, low sensitivity, and duplication bias when compared to array CGH platform. Thus careful evaluation and additional validation is highly recommended.
Yan Guo and Quanghu Sheng have equally contributed to this paper.
All data were generated from Vanderbilt Technologies for Advanced Genomics. The authors would like to thank Margot Bjoring for her editorial support.
- S. B. Ng, K. J. Buckingham, C. Lee et al., “Exome sequencing identifies the cause of a mendelian disorder,” Nature Genetics, vol. 42, no. 1, pp. 30–35, 2010.
- J. T. Glessner, K. Wang, G. Cai et al., “Autism genome-wide copy number variation reveals ubiquitin and neuronal genes,” Nature, vol. 459, no. 7246, pp. 569–572, 2009.
- T. L. Yang, Y. Guo, H. Shen et al., “Copy number variation on chromosome 10q26.3 for obesity identified by a genome-wide study,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 1, pp. E191–E195, 2013.
- A. Bergamaschi, Y. H. Kim, P. Wang et al., “Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer,” Genes Chromosomes and Cancer, vol. 45, no. 11, pp. 1033–1040, 2006.
- M. Moroni, S. Veronese, S. Benvenuti et al., “Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study,” The Lancet Oncology, vol. 6, no. 5, pp. 279–286, 2005.
- F. Cappuzzo, C. Ligorio, L. Toschi et al., “EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC),” Journal of Thoracic Oncology, vol. 2, no. 5, pp. 423–429, 2007.
- A. Vasson, C. Leroux, L. Orhant et al., “Custom oligonucleotide array-based CGH: a reliable diagnostic tool for detection of exonic copy-number changes in multiple targeted genes,” European Journal of Human Genetics, vol. 21, no. 9, pp. 977–987, 2013.
- H. Lybæk, L. A. Meza-Zepeda, S. H. Kresse, T. Høysæter, V. M. Steen, and G. Houge, “Array-CGH fine mapping of minor and cryptic HR-CGH detected genomic imbalances in 80 out of 590 patients with abnormal development,” European Journal of Human Genetics, vol. 16, no. 11, pp. 1318–1328, 2008.
- J. Schoumans, K. Nielsen, I. Jeppesen et al., “A comparison of different metaphase CGH methods for the detection of cryptic chromosome aberrations of defined size,” European Journal of Human Genetics, vol. 12, no. 6, pp. 447–454, 2004.
- K. Hashimoto, N. Mori, T. Tamesa et al., “Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH,” Modern Pathology, vol. 17, no. 6, pp. 617–622, 2004.
- A. Abyzov, A. E. Urban, M. Snyder, and M. Gerstein, “CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing,” Genome Research, vol. 21, no. 6, pp. 974–984, 2011.
- V. Boeva, T. Popova, K. Bleakley et al., “Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data,” Bioinformatics, vol. 28, no. 3, pp. 423–425, 2012.
- D. Y. Chiang, G. Getz, D. B. Jaffe et al., “High-resolution mapping of copy-number alterations with massively parallel sequencing,” Nature Methods, vol. 6, no. 1, pp. 99–103, 2009.
- A. Magi, M. Benelli, S. Yoon, F. Roviello, and F. Torricelli, “Detecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm,” Nucleic Acids Research, vol. 39, no. 10, article e65, 2011.
- P. Medvedev, M. Fiume, M. Dzamba, T. Smith, and M. Brudno, “Detecting copy number variation with mated short reads,” Genome Research, vol. 20, no. 11, pp. 1613–1622, 2010.
- C. A. Miller, O. Hampton, C. Coarfa, and A. Milosavljevic, “ReadDepth: a parallel R package for detecting copy number alterations from short sequencing reads,” PLoS ONE, vol. 6, no. 1, Article ID e16327, 2011.
- S. M. Waszak, Y. Hasin, T. Zichner et al., “Systematic inference of copy-number genotypes from personal genome sequencing data reveals extensive olfactory receptor gene content diversity,” PLoS Computational Biology, vol. 6, no. 11, Article ID e1000988, 2010.
- J. F. Sathirapongsasuti, H. Lee, B. A. J. Horst et al., “Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV,” Bioinformatics, vol. 27, no. 19, pp. 2648–2654, 2011.
- N. Krumm, P. H. Sudmant, A. Ko et al., “Copy number variation detection and genotyping from exome sequence data,” Genome Research, vol. 22, no. 8, pp. 1525–1532, 2012.
- G. Klambauer, K. Schwarzbauer, A. Mayr et al., “cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate,” Nucleic Acids Research, vol. 40, no. 9, article e69, 2012.
- M. I. Love, A. Myišičková, R. Sun, V. Kalscheuer, M. Vingron, and S. A. Haas, “Modeling read counts for CNV detection in exome sequencing data,” Statistical Applications in Genetics and Molecular Biology, vol. 10, no. 1, article 52, 2011.
- V. Plagnol, J. Curtis, M. Epstein et al., “A robust model for read count data in exome sequencing experiments and implications for copy number variant calling,” Bioinformatics, vol. 28, no. 21, pp. 2747–2754, 2012.
- A. Gusnanto, H. M. Wood, Y. Pawitan, P. Rabbitts, and S. Berri, “Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data,” Bioinformatics, vol. 28, no. 1, pp. 40–47, 2012.
- J. Li, R. Lupat, K. C. Amarasinghe et al., “CONTRA: copy number analysis for targeted resequencing,” Bioinformatics, vol. 28, no. 10, pp. 1307–1313, 2012.
- H. Li and R. Durbin, “Fast and accurate short read alignment with Burrows-Wheeler transform,” Bioinformatics, vol. 25, no. 14, pp. 1754–1760, 2009.
- H. Li, B. Handsaker, A. Wysoker et al., “The sequence alignment/Map format and SAMtools,” Bioinformatics, vol. 25, no. 16, pp. 2078–2079, 2009.
- A. McKenna, M. Hanna, E. Banks et al., “The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data,” Genome Research, vol. 20, no. 9, pp. 1297–1303, 2010.
- P. J. A. Cock, C. J. Fields, N. Goto, M. L. Heuer, and P. M. Rice, “The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants,” Nucleic Acids Research, vol. 38, no. 6, pp. 1767–1771, 2009.